Evidence map›Paper›PMID 37941812›Full record

ReviewJournal of hepatocellular carcinoma2023

Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma.

Giulia Francesca Manfredi, Ciro Celsa, Chloe John, Charlotte Jones, Nicole Acuti, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, James Korolewicz, Matthias Pinter, Alessandra Gennari and 10 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of hepatocellular carcinoma, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. [Research Advances in the Roles of High-Altitude Hypoxic Stress in Hepatocellular Carcinoma].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 3 countries.

Giulia Francesca ManfrediDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Ciro CelsaDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Chloe JohnDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Charlotte JonesDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Nicole AcutiDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Bernhard ScheinerDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Claudia Angela Maria FulgenziDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
James KorolewiczDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Matthias PinterDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Alessandra GennariDivision of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
Francesco A MauriDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Mario PirisiDepartment of Translational Medicine, Università Del Piemonte Orientale, Novara, Italy.ORCID 0000-0001-9740-0155
Rosalba MinisiniDepartment of Translational Medicine, Università Del Piemonte Orientale, Novara, Italy.
Federica VincenziDepartment of Translational Medicine, Università Del Piemonte Orientale, Novara, Italy.
Michela BurloneDivision of Internal Medicine, AOU Maggiore della Carità, Novara, Italy.
Cristina RigamontiDepartment of Translational Medicine, Università Del Piemonte Orientale, Novara, Italy.
Matteo DonadonDepartment of Health Science, Università Del Piemonte Orientale, Novara, Italy.
Giuseppe CabibboSection of Gastroenterology & Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy.ORCID 0000-0002-0946-3859
Antonio D'AlessioDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
David James PinatoDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.ORCID 0000-0002-3529-0103
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITHammersmith Hospital · GBMedical University of Vienna · ATUniversità Campus Bio-Medico · ITUniversity of Palermo · IT

Funding

Wellcome Trust
6 · The paper itself

Abstract

Systemic treatment for advanced hepatocellular carcinoma (HCC) has been revolutionized over the last few years following the approval of immune checkpoint inhibitors (ICI). Despite the promising survival extension seen with ICI combination regimens, responses are not universally seen and the optimal partner for programmed cell death 1 pathway inhibitors remains to be identified. Even fewer encouraging results have been demonstrated with ICI used for monotherapy. Several mechanisms of resistance have been described so far, involving characteristics of cancer cells (intrinsic mechanisms) and of the surrounding tumor microenvironment (extrinsic mechanisms). Factors related to therapy may also contribute to the development of resistance. Increasing research efforts are being dedicated to the discovery of novel approaches and targets to overcome resistance, some of which may be introduced into clinic in the future. Herein we describe a selection of resistance mechanisms that have been involved in impairing response to ICI and propose potential therapeutic approaches to overcome resistance.

Indexed as

immune checkpoint inhibitorsliver cancerrecurrencetumor microenvironment

Identifiers

PMID37941812
PMCPMC10629523
OpenAlexW4388301636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.